The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex ...

President Trump wants pharmaceutical production to return to the United States. A shuttered factory in Louisiana shows how ...

The Food and Drug Administration said it will be taking steps to speed up the approval process for developing generic biological drugs, an effort aimed at increasing cheaper competition among ...

The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative ...

Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for ...

Move is latest broadside by Trump administration against pharmaceuticals industry that fought to derail changes ...

Lawmakers at the helm of the Senate Special Committee on Aging have proposed a sweeping series of changes that could ...

A new antimicrobial generic drug was approved by officials with the FDA for the treatment of canine skin infections: ...

Developers of biosimilars -- medicines that are near-identical copies of biologic drugs -- will no longer be required to conduct clinical trials to prove effectiveness.

A trade group representing generic drugmakers is seeking an injunction to thwart a provision of a new Connecticut law that ...

Last year, these treatments accounted for 75% of the $236B in annual sales set to vanish with the loss of exclusivity.